Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus casei CAAS36
- Development stage
- Preclinical
- Lead developer
- Institute of Food Science and Technology, Chinese Academy of Agricultural Science
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus casei CAAS36 is a specific probiotic strain being studied for its potential to treat hyperlipidemia. [1-1] It was isolated from traditional homemade dairy products in Inner Mongolia, China. [1-19, 1-15] As a probiotic, it is believed to work by modulating the composition and metabolic pathways of the gut microbiota. [1-15] In preclinical studies, administration of L. casei CAAS36 resulted in significant reductions in key lipid markers, including a 29.9% decrease in total cholesterol, a 29.4% decrease in LDL-C, and a 32.6% decrease in triglycerides. [1-4] The research is being conducted by academic institutions in China, and there is currently no commercial developer or brand name associated with this strain.
02
Targets
TLR2 (Toll-like Receptor 2)MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on Lactobacillus casei CAAS36.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus casei CAAS36.